Eran Perry - Compugen Director
| CGEN Stock | ILA 581.00 9.00 1.57% |
Director
Mr. Eran Perry was appointed Director at Compugen Ltd. effective July 1, 2019. His work experience includes the following roles CoFounder, Managing Director and Chairman of the Investment Committee of MII Fund and Labs, CoFounder and Board Member of ICD Pharma, Musli Thyropeutics, Seanergy Dermatology and Follicle Pharma, Managing Director and Partner of Israel Healthcare Ventures, Consultant at McKinsey Company and Member of the global marketing group at Novartis Oncology. He holds a LLB degree and a BS degree in Computer Science and Mathematics, both from Tel Aviv University and a MBA degree from Columbia University. since 2019.
| Tenure | 5 years |
| Professional Marks | MBA |
| Phone | (972) 3 765 8555 |
| Web | www.cgen.com |
Compugen Management Efficiency
The company has return on total asset (ROA) of (0.2301) % which means that it has lost $0.2301 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4394) %, meaning that it generated substantial loss on money invested by shareholders. Compugen's management efficiency ratios could be used to measure how well Compugen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Sarit Firon | Evogene | 52 | |
| Joseph Cowan | Nice | 70 | |
| Abraham Havron | Kamada | 71 | |
| Itzhak Krinsky | Kamada | 65 | |
| Yuli Tamir | Elbit Systems | 65 | |
| Yehoshua Gleitman | Elbit Systems | 69 | |
| Yocheved Dvir | Nice | 66 | |
| Yehoshua Ehrlich | Nice | 69 | |
| Tuvia Shoham | Kamada | 70 | |
| Yoram BenZeev | Elbit Systems | 74 | |
| Leon Recanati | Evogene | 71 | |
| Leo Apotheker | Nice | 65 | |
| Zehava Simon | Nice | 60 | |
| Gwen Melincoff | Kamada | 67 | |
| Ziv Kop | Evogene | 46 | |
| Jonathan Hahn | Kamada | 32 | |
| Avraham Guzman | Tower Semiconductor | 79 | |
| Dov Ninveh | Elbit Systems | 71 | |
| Oded Shoseyov | Evogene | 62 | |
| Ilan Flato | Tower Semiconductor | 61 | |
| Estery GilozRan | Kamada | 44 | |
Management Performance
| Return On Equity | -0.44 | |||
| Return On Asset | -0.23 |
Compugen Leadership Team
Elected by the shareholders, the Compugen's board of directors comprises two types of representatives: Compugen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Compugen. The board's role is to monitor Compugen's management team and ensure that shareholders' interests are well served. Compugen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Compugen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alberto Sessa, Chief Officer | ||
| Michal Preminger, Director | ||
| Rivka Schwartz, VP Discovery | ||
| Paul Sekhri, Chairman of the Board | ||
| Henry MD, VP Officer | ||
| Arie Ovadia, Independent External Director | ||
| Zurit Levine, Vice President - Research and Discovery | ||
| Eran Perry, Director | ||
| Ari Krashin, Chief Financial Officer | ||
| Sanford Zweifach, Director | ||
| Gilead Halevy, Director | ||
| Anat CohenDayag, President, Chief Executive Officer, Director | ||
| Ruth Arnon, Independent Director | ||
| Yvonne Naughton, Head Communications | ||
| Kinneret Savitsky, Director | ||
| Henry Adewoye, Chief Medical Officer | ||
| Dorit Amitay, VP HR | ||
| Yair Aharonowitz, Independent External Director | ||
| Eran Dor, Gen Sec | ||
| JeanPierre Bizzari, Director | ||
| Oliver Froescheis, Sr Devel | ||
| John Hunter, VP of Antibody RandD and Site Head of Compugen USA Inc |
Compugen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Compugen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | 12.53 M | |||
| Shares Outstanding | 86.62 M | |||
| Shares Owned By Insiders | 5.50 % | |||
| Shares Owned By Institutions | 27.56 % | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 46.89 X | |||
| Revenue | 6 M | |||
| Gross Profit | 5.32 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Compugen Stock
When determining whether Compugen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Compugen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Compugen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Compugen Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Compugen Stock refer to our How to Trade Compugen Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.